European top innovators: R&D intensity drives returns European top innovators: R&D intensity drives returns European top innovators: R&D intensity drives returns

European top innovators: R&D intensity drives returns

Equities 5 minutes to read
Peter Garnry

Head of Saxo Strats

Summary:  R&D is key for long-term shareholder returns and generally understanding the drivers of increasing returns. One key driver is Wright's Law (cost reduction with cumulative output) and Economies of Scale. High ROIC is a hallmark of competitive edge for generating superior returns and high ROIC often reflects industry or technology shifts. Superstar firms increasingly invest in proprietary software for competitive advantage and are outspending rivals in this area. We are used to successful US based technology companies but in this equity note we focus on Europe’s innovation stars like Novo Nordisk, ABB, and ASML that excel in R&D and innovation across diverse industries.

R&D is an important factor to consider for the long-term investor

In a recent research note Increasing Returns – Identifying Returns and What Drives Them by Michael Mauboussin and Dan Callahan the authors talk about what drives equity returns. The table from their note (see below) shows the five main drivers of increasing returns for companies and their shareholders. It worth reflecting on as an investor as it can help you identify whether a company that you are considering investing in has one of more of these drivers of long-term increasing returns. For Tesla Wright’s Law is at play which is the Learning by Doing factor as cost per unit (EVs) drops by about 20% for every doubling of cumulative output. The force often goes hand in hand with the Economies of Scale factor as increasing cumulative output also increase volume of production up to a certain point.

The hallmark of competitiveness and these increasing returns are a high return on invested capital (ROIC) which reflects that a company has a structure and offers a product that yield a return on capital surpassing the cost of capital. High ROIC figures for an industry are often a sign of significant industry or technology changes. Historical data suggests that abnormal ROIC does tend to revert to the long-term average but that the time period is different across industries and technologies.

One of the findings around companies with increasing returns is that superstar firms substantially outspend their competitors on intangible assets. Increasingly those investments are going into proprietary software and those investments are now growing faster than traditional R&D, acquisitions, advertising, and lobbying. In other words, software is key driver of future moats for many companies. In the old economy advertising was important but today software is more important. High R&D spending is generally associated with companies innovating faster than competitors and winning long-term.

We are used to talk about US exceptionalism because the US won the digitalization with Europe’s technology sector sleeping at the steering wheel. But what about Europe, does the continent offer any superstars when it comes to R&D and innovation? The list below highlights 20 European publicly listed companies. We have filtered on those with a market cap above €10bn, ROIC above 12%, and then selected those companies with the highest R&D spending to revenue. We have also chosen companies across a wide range of industries as the list would otherwise be concentrated too much around pharmaceuticals and semiconductors.

Source: Counterpoint Global

Three European superstars: Novo Nordisk, ABB, and ASML

As we cannot highlight all the companies in the list we have chosen three companies that are innovators in different industries.

Novo Nordisk: Leading the obesity treatment boom

Novo Nordisk is one of the leading insulin manufacturers in the world together with US based Eli Lilly. The Danish pharmaceutical company has recently made key breakthroughs in obesity treatment using the same active ingredient used in its insulin. This has unlocked an almost infinite demand for its obesity  drug called Wegovy and catapulted revenue growth to its highest level in the firm’s entire history. The pharmaceutical industry of Europe is significant industry and important value driver of European equity markets as the list also shows.

Source: Novo Nordisk investor presentation

ABB: Industrial and automation powerhouse

ABB is an industrial giant of Europe and a leader in robotics, automation technology, and power solutions. The new wave of electrification ushering over the world with electrification of transportation, heating, and running data centres for digitalization is benefitting ABB. The company’s largest segment is called Electrification which is engaged in everything related to the electrification from power solution, EV charging networks, grid technology and power generation technologies. This segment has been the key driver of the company’s record margin expansion.

Source: ABB investor presentation

ASML: Monopoly in equipment used for advanced AI chips

The crown jewel of Europe’s technology sector manufacturing advanced lithography machines used for advanced chip production. The most advanced AI chips in the world powering the boom in AI are manufactured using extreme ultraviolet lithography machines (EUV). ASML basically holds a close to monopoly in this industry and EUV accounted for 42% of net system sales in 2023. No matter who wins the chip battle (Nvidia vs AMD vs Intel) or who wins the foundry battle (TSMC vs Intel), the industry must use ASML machines and thus the company is well-positioned for the AI boom and general Internet of Things trend over the coming decades.
Source: ASML investor presentation


The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
Notification on Non-Independent Investment Research (
Full disclaimer (
Full disclaimer (

Saxo Bank (Schweiz) AG
The Circle 38

Contact Saxo

Select region


All trading carries risk. Losses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money. To help you understand the risks involved we have put together a general Risk Warning series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. The KIDs can be accessed within the trading platform. Please note that the full prospectus can be obtained free of charge from Saxo Bank (Switzerland) Ltd. or the issuer.

This website can be accessed worldwide however the information on the website is related to Saxo Bank (Switzerland) Ltd. All clients will directly engage with Saxo Bank (Switzerland) Ltd. and all client agreements will be entered into with Saxo Bank (Switzerland) Ltd. and thus governed by Swiss Law. 

The content of this website represents marketing material and has not been notified or submitted to any supervisory authority.

If you contact Saxo Bank (Switzerland) Ltd. or visit this website, you acknowledge and agree that any data that you transmit to Saxo Bank (Switzerland) Ltd., either through this website, by telephone or by any other means of communication (e.g. e-mail), may be collected or recorded and transferred to other Saxo Bank Group companies or third parties in Switzerland or abroad and may be stored or otherwise processed by them or Saxo Bank (Switzerland) Ltd. You release Saxo Bank (Switzerland) Ltd. from its obligations under Swiss banking and securities dealer secrecies and, to the extent permitted by law, data protection laws as well as other laws and obligations to protect privacy. Saxo Bank (Switzerland) Ltd. has implemented appropriate technical and organizational measures to protect data from unauthorized processing and disclosure and applies appropriate safeguards to guarantee adequate protection of such data.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.